AZD2389
Sponsors
AstraZeneca
Conditions
Advanced Chronic Liver DiseaseHealthy ParticipantsHepatic CirrhosisHepatic ImpairmentLiver Fibrosis
Phase 1
A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants
CompletedNCT06138795
Start: 2023-11-20End: 2025-08-24Updated: 2025-09-09
A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389
CompletedNCT06812780
Start: 2025-02-04End: 2025-09-04Updated: 2025-09-24
A Study to Investigate the Pharmacokinetics of AZD2389 When Administered Alone and in Combination With Itraconazole in Healthy Participants
CompletedNCT06846528
Start: 2025-02-26End: 2025-04-23Updated: 2025-04-29
A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants
CompletedNCT06973005
Start: 2025-05-08End: 2025-07-18Updated: 2025-07-24
A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine
CompletedNCT06974565
Start: 2025-05-12End: 2025-07-18Updated: 2025-07-25
The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.
CompletedNCT07069725
Start: 2025-05-26End: 2026-07-02Updated: 2026-07-27
Phase 2
A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.
CompletedNCT06750276
Start: 2024-12-06End: 2025-07-28Updated: 2026-07-06
Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis
RecruitingNCT07610837
Start: 2026-05-07End: 2027-07-07Target: 104Updated: 2026-09-01